Alvimedica announces the CE mark of NiTiDES™, its new polymer free self-expanding Amphilimus™ eluting stent for SFA lesions.
ALVIMEDICA, Istanbul, 31st of May 2021. In the treatment of SFA lesions the option of DES implantation is just related to the first generation of Drug Eluting Stents which releases Paclitaxel, a cytotoxic drug still under scrutiny for its clinical safety. The next generation of such devices is starting today with NiTiDES™, a highly innovative self-expanding DES eluting a Sirolimus based formulation named Amphilimus™ (Sirolimus + Fatty Acid). The Sirolimus drug is very well known for its cytostatic action, which guarantees a high safety profile without compromising efficacy.